Bioenvision to Host Third Quarter 2006 Financial Results Conference Call

Bioenvision (NASDAQ: BIVN) today announced that the
Company will host a conference call with the financial community to
discuss the third quarter 2006 financial results on Monday, May 15,
2006 at 10:00 a.m. EST.
   To participate in the live call by telephone, please dial
877-715-5320 from the U.S. and Canada or 973-582-2853 from outside the
U.S. A telephone replay of the call will be available beginning at
12:00 p.m. EST May 15th until 11:59 p.m. EST May 29th by dialing
877-519-4471 or 973-341-3080 and entering reservation number 7373873.
   Those interested in listening to the conference call live via the
Internet may do so by visiting www.vcall.com where a link to
Bioenvision's conference call can be found. Please go to the web site
15 minutes prior to its start to register, download, and install the
necessary audio software. A replay will be available for 14 days.

   About Bioenvision

   Bioenvision's primary focus is the acquisition, development and
distribution of compounds and technologies for the treatment of
cancer. Bioenvision has a broad pipeline of products for the treatment
of cancer, including: Clofarabine (in co-development with Genzyme
Corporation), Modrenal(R) (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products in clinical trials.
Bioenvision is also developing anti-infective technologies, including
Suvus for hepatitis-C and the OLIGON technology; an advanced
biomaterial that has been incorporated into various FDA approved
medical devices. For more information on Bioenvision please visit our
web site at www.bioenvision.com.

   Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.